Phaseline

Companies › HuniLife Biotechnology

HuniLife Biotechnology: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Nov 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
HuL001
Anti-ENO1 monoclonal antibody
ENO1Phase 1Multiple Myeloma RefractoryNov 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07210047HuL001Phase 1Multiple Myeloma RefractoryOncologyNov 2027

Targets

ENO1 (1)

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.